Novel design of dual-action Pt(IV) anticancer pro-drugs based on cisplatin and derivatives of the Tyrosine Kinase Inhibitors imatinib and nilotinib
This article is licensed under aCreative Commons Attribution 3.0 Unported Licence.Darren Fergal Beirne, Barbara Farkas, Chiara Donati, Valentina Gandin, Isabel Rozas, Trinidad Velasco-Torrijos, Diego Montagner Tyrosine Kinases (TKs) are emerging as important targets in cancer therapy and some of their inhibitors TKi (i.e. Imatinib and Nilotinib) are FDA approved drugs that are used as selective... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Darren Fergal Beirne Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Gleevec | Nilotinib | Tasigna | Trinidad and Tobago Health